TOP > 外国特許検索 > METHOD FOR PREVENTION AND TREATMENT OF METABOLIC SYNDROME THROUGH THE INHIBITION OF PSGL-1

METHOD FOR PREVENTION AND TREATMENT OF METABOLIC SYNDROME THROUGH THE INHIBITION OF PSGL-1 コモンズ

外国特許コード F100002336
掲載日 2010年12月14日
出願国 世界知的所有権機関(WIPO)
国際出願番号 2009JP059045
国際公開番号 WO 2009139459
国際出願日 平成21年5月15日(2009.5.15)
国際公開日 平成21年11月19日(2009.11.19)
優先権データ
  • 特願2008-128086 (2008.5.15) JP
発明の名称 (英語) METHOD FOR PREVENTION AND TREATMENT OF METABOLIC SYNDROME THROUGH THE INHIBITION OF PSGL-1 コモンズ
発明の概要(英語) Disclosed is a prophylactic and/or therapeutic agent which can exhibit an effect by itself on the prevention and/or treatment of a basic condition of a lifestyle-related disease such as metabolic syndrome and type-2 diabetes. Also disclosed is a method for the screening of the prophylactic and/or therapeutic agent. Specifically disclosed is a prophylactic and/or therapeutic agent for metabolic diseases, which comprises an inhibitor of PSGL-1 as an active ingredient.
従来技術、競合技術の概要(英語) BACKGROUND ART
In advanced countries, life-style related diseases, in particular the metabolic and significantly increased in recent years of affected individuals, are a critical issue in the medical. In a patient with metabolic syndrome, visceral fat type obesity, hyperglycemia, hypertension, hyperlipidemia and symptoms such as heavy product, the product of the severity of the condition, such as myocardial infarction or cerebral artery disease is likely to develop is high. The diagnostic criteria for metabolic syndrome is not unified worldwide, for example in Japan, visceral fat type obesity and essential item, further high blood pressure, abnormal serum lipid levels of hyperglycemia and 2 corresponds to the two or more of the metabolic syndrome is diagnosed.
Of the metabolic syndrome is epidemic in recent years, largely for lack of exercise and, as an objective the treatment heretofore dietary and exercise regimens have been emphasized. However, these therapies are, a fundamental improvement such the patient's own life style often force, therefore it is difficult to realize in many cases. On the other hand, the major metabolic syndrome hypertension is a disease state, for each of the serum hyperglycemia and dyslipidemia and drug therapy has been attempted, for example, in the treatment of low HDL - high triglyceride/fibrate or the statin drug is; altered glucose metabolism is sulfonylurea agents, rapid-acting insulin secretagogues, or insulin resistance-improving agent α - glucosidase inhibitors; hypertension an angiotensin-converting enzyme inhibitor or adrenaline α receptor antagonist and the like are used. However, these drug therapies are, medical costs are expensive and not necessarily therapeutic efficacy such as to ensure that there are problems. In addition, visceral fat type obesity drug therapy includes, central appetite suppressants and indirectly by the prevention or treatment is being performed only.
Metabolic syndrome or type 2 diabetes including in the development of life-style related diseases, the importance of insulin resistance has been widely recognized. Insulin resistance is a, skeletal muscle cells, liver cells, such as in fat cells, by a reduction in insulin sensitivity, insulin secretion is maintained but, refers to a decrease in its action. Insulin resistance and hyperinsulinemia, glucose intolerance and then, further induces abnormal lipid metabolism and hypertension is considered to be a (non-patent document 1). Is a development mechanism of insulin resistance are not always fully apparent not, provided by the conventional nonalcoholic state and lack of exercise and increased visceral fat accumulation has been regarded as important. Further, in recent years, obesity and insulin resistance is interposed between the inflammation have been revealed and, the size of the fat cells, necrosis and coronary surrounding it is macrophage accumulation, which leads to inflammation and insulin resistance is thus spread.
Is PSGL-1, leukocytes and vascular endothelial cells and cells involved in the adhesion of the surface of a molecule cloned as a ligand for a selectin P- membrane protein (patent document 1, non-patent document 2). Is PSGL-1, and disulfide bond 220kDa, Most blood leukocytes (for example, neutrophils, monocytes, macrophages, B a subset of cells, and all T cells) expressing PSGL-1 is known. Inflammation is extremely important in the migration of leukocytes to the injured tissue in the course of and invasion of a wide variety of cell adhesion molecule is responsible, in the early stages of inflammation observed is a phenomenon called rolling, specific to them Selectin sugar chain interacting with the ligands (for example P- the interaction of selectins PSGL-1) known to be performed via the (non-patent document 3 and 4). However, type 2 diabetes or metabolic syndrome including lifestyle-related disease in the pathogenesis of, PSGL-1 plays an important role has not been known hitherto.
  • 出願人(英語)
  • ※2012年7月以前掲載分については米国以外のすべての指定国
  • National University Corporation Okayama University
  • 発明者(英語)
  • SHIKATA, Kenichi
  • MAKINO, Hirofumi
  • SATO, Chikage
国際特許分類(IPC)
指定国 National States: AE AG AL AM AO AT AU AZ BA BB BG BH BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DO DZ EC EE EG ES FI GB GD GE GH GM GT HN HR HU ID IL IN IS JP KE KG KM KN KP KR KZ LA LC LK LR LS LT LU LY MA MD ME MG MK MN MW MX MY MZ NA NG NI NO NZ OM PG PH PL PT RO RS RU SC SD SE SG SK SL SM ST SV SY TJ TM TN TR TT TZ UA UG US UZ VC VN ZA ZM ZW
ARIPO: BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW
EAPO: AM AZ BY KG KZ MD RU TJ TM
EPO: AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LT LU LV MC MK MT NL NO PL PT RO SE SI SK TR
OAPI: BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

PAGE TOP

close
close
close
close
close
close